Home › Companies › JANUX THERAPEUTICS INC. › 2024-2025
Download data (CSV): ballot items · votes by manager · column guide.
Compiled from SEC Form N-PX filings and JANUX THERAPEUTICS INC.’s Form 8-K, filed June 13, 2025 (Item 5.07 on EDGAR). Page generated November 20, 2026.
Meeting of June 11, 2025: 5 items on JANUX THERAPEUTICS INC.’s Form 8-K, filed June 13, 2025: 3 elected · 2 approved.
Significant dissent: 1 director (22.4% against).
Notable dissent: 2 directors (19.1%, 17.7% against).
Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided
Proxy season: 2023-2024 2024-2025 2025-2026
Activist investors: Ra Capital Management, L.P. (13D, 19.9%, as of March 10, 2025) · Nantahala Capital (13F, 1.4%, as of September 30, 2026)
Explore JANUX THERAPEUTICS INC. in the interactive database Compare manager voting policies
These tallies are JANUX THERAPEUTICS INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 13, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Support (of votes cast) | Reported outcome | Voting standard |
|---|---|---|---|---|---|---|---|---|
| Elect Director: David Campbell, Ph.D. | 44,740,538 | -- | -- | 9,631,829 | 1,866,944 | 82% | Elected | — |
| Elect Director: Ron Barrett, Ph.D. | 44,005,362 | -- | -- | 10,367,005 | 1,866,944 | 81% | Elected | — |
| Elect Director: Winston Kung | 42,187,543 | -- | -- | 12,184,824 | 1,866,944 | 78% | Elected | — |
| 2. Ratification of the Selection of Independent Registered Public Accounting Firm | 56,152,990 | 27,381 | 58,941 | -- | -- | 99.9% | Approved | — |
| 3. Advisory Vote on Executive Compensation | 53,205,989 | 1,150,947 | 15,431 | -- | 1,866,944 | 98% | Approved | — |
Source: JANUX THERAPEUTICS INC., Form 8-K, filed with the SEC on June 13, 2025 — read the filing on EDGAR.
See voting trends for Health Care companies, 2024-2025: shareholder support by sector and by company size.
232 asset managers disclosed a vote on at least one JANUX THERAPEUTICS INC. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of JANUX THERAPEUTICS INC.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Combines 2 wordings of this item as funds reported it.
82% Majority: yes · of votes cast
Description as filed by funds: To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: David Campbell, Ph.D.
JANUX THERAPEUTICS INC.’s own tally for this item (“Elect Director: David Campbell, Ph.D.”): 44,740,538 for, 9,631,829 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resigna…”
Support: 82% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 14,627,558 for, 1,840,349 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,262,889 | 0 | 0 | 0 | For |
| Vanguard | 2,207,727 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 0 | 0 | 0 | 1,328,416 | Withhold |
| BlackRock | 1,319,820 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,066,406 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 445,252 | 0 | 0 | 0 | For |
| Putnam | 333,552 | 0 | 0 | 0 | For |
| Charles Schwab | 276,724 | 0 | 0 | 0 | For |
| State Street | 258,462 | 0 | 0 | 337 | For |
| Columbia Threadneedle | 238,425 | 0 | 0 | 0 | For |
| Aberdeen | 224,788 | 0 | 0 | 0 | For |
| Invesco | 203,548 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 180,836 | Withhold |
| TIAA | 121,036 | 0 | 0 | 0 | For |
| Equitable | 97,860 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 6,132 | 0 | 0 | 84,722 | Mixed |
| Delaware/Macquarie | 0 | 0 | 0 | 76,601 | Withhold |
| Russell Investments | 60,914 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 53,817 | 0 | 0 | 0 | For |
| Hartford | 51,244 | 0 | 0 | 0 | For |
| Lincoln Financial | 31,677 | 0 | 0 | 16,621 | Mixed |
| JPMorgan | 48,262 | 0 | 0 | 0 | For |
| Tema ETF Trust | 46,453 | 0 | 0 | 0 | For |
| Northern Trust | 41,496 | 0 | 0 | 0 | For |
| John Hancock | 24,796 | 0 | 0 | 11,657 | Mixed |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
81% Majority: yes · of votes cast
Description as filed by funds: To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Ronald Barrett, Ph.D.
JANUX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Ron Barrett, Ph.D.”): 44,005,362 for, 10,367,005 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resigna…”
Support: 81% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 14,255,451 for, 2,212,456 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,262,889 | 0 | 0 | 0 | For |
| Vanguard | 2,207,727 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 0 | 0 | 0 | 1,328,416 | Withhold |
| BlackRock | 1,319,820 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,066,406 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 445,252 | 0 | 0 | 0 | For |
| Putnam | 333,552 | 0 | 0 | 0 | For |
| Charles Schwab | 276,724 | 0 | 0 | 0 | For |
| State Street | 258,462 | 0 | 0 | 337 | For |
| Columbia Threadneedle | 238,425 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 224,788 | Withhold |
| Invesco | 203,548 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 180,836 | Withhold |
| TIAA | 121,036 | 0 | 0 | 0 | For |
| Equitable | 57,783 | 0 | 0 | 40,077 | Mixed |
| Bridge Builder Trust | 6,132 | 0 | 0 | 84,722 | Mixed |
| Delaware/Macquarie | 0 | 0 | 0 | 76,601 | Withhold |
| Russell Investments | 60,914 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 53,817 | 0 | 0 | 0 | For |
| Hartford | 51,244 | 0 | 0 | 0 | For |
| Lincoln Financial | 31,677 | 0 | 0 | 16,621 | Mixed |
| JPMorgan | 48,262 | 0 | 0 | 0 | For |
| Tema ETF Trust | 46,453 | 0 | 0 | 0 | For |
| Northern Trust | 0 | 0 | 0 | 41,496 | Withhold |
| John Hancock | 24,796 | 0 | 0 | 11,657 | Mixed |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Combines 2 wordings of this item as funds reported it.
78% Majority: yes · of votes cast
Description as filed by funds: To elect the three nominees for Class I Director named in the accompanying proxy statement to serve for three-year terms until the 2028 Annual Meeting of Stockholders: Winston Kung
JANUX THERAPEUTICS INC.’s own tally for this item (“Elect Director: Winston Kung”): 42,187,543 for, 12,184,824 withheld, per its Form 8-K filed June 13, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.
Reported outcome: Elected, in the filing’s own words: “Proposal 1: Election of Directors The Company's stockholders elected the three persons listed below as Class I directors, each to serve until the Company's 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or until their earlier death, resigna…”
Support: 78% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 13,961,474 for, 2,506,433 withheld.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,262,889 | 0 | 0 | 0 | For |
| Vanguard | 2,207,727 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 0 | 0 | 0 | 1,328,416 | Withhold |
| BlackRock | 1,319,820 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,066,406 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 445,252 | 0 | 0 | 0 | For |
| Putnam | 333,552 | 0 | 0 | 0 | For |
| Charles Schwab | 0 | 0 | 0 | 276,724 | Withhold |
| State Street | 258,462 | 0 | 0 | 337 | For |
| Columbia Threadneedle | 238,425 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 0 | 0 | 224,788 | Withhold |
| Invesco | 203,548 | 0 | 0 | 0 | For |
| Victory Capital | 0 | 0 | 0 | 180,836 | Withhold |
| TIAA | 121,036 | 0 | 0 | 0 | For |
| Equitable | 57,783 | 0 | 0 | 40,077 | Mixed |
| Bridge Builder Trust | 6,132 | 0 | 0 | 84,722 | Mixed |
| Delaware/Macquarie | 0 | 0 | 0 | 76,601 | Withhold |
| Russell Investments | 0 | 0 | 0 | 60,914 | Withhold |
| QUANTITATIVE MASTER SERIES LLC | 53,817 | 0 | 0 | 0 | For |
| Hartford | 51,244 | 0 | 0 | 0 | For |
| Lincoln Financial | 31,677 | 0 | 0 | 16,621 | Mixed |
| JPMorgan | 48,262 | 0 | 0 | 0 | For |
| Tema ETF Trust | 46,453 | 0 | 0 | 0 | For |
| Northern Trust | 41,496 | 0 | 0 | 0 | For |
| John Hancock | 24,796 | 0 | 0 | 11,657 | Mixed |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Combines 9 wordings of this item as funds reported it.
98% Approved · of votes cast
Description as filed by funds: Approval, on an advisory basis, of the compensation of our named executive officers ("Say-On-Pay"), as disclosed in the accompanying Proxy Statement.
JANUX THERAPEUTICS INC.’s own tally for this item (“3. Advisory Vote on Executive Compensation”): 53,205,989 for, 1,150,947 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 3: Advisory Vote on Executive Compensation The Company's stockholders approved, on an advisory (non-binding) basis, the compensation of our named executive officers as disclosed in the Proxy Statement.”
Support: 98% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,262,889 | 0 | 0 | 0 | For |
| Vanguard | 2,207,727 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,328,416 | 0 | 0 | 0 | For |
| BlackRock | 1,319,820 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,066,406 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 445,252 | 0 | 0 | 0 | For |
| Putnam | 333,552 | 0 | 0 | 0 | For |
| Charles Schwab | 276,724 | 0 | 0 | 0 | For |
| State Street | 258,784 | 15 | 0 | 0 | For |
| Columbia Threadneedle | 238,425 | 0 | 0 | 0 | For |
| Aberdeen | 0 | 224,788 | 0 | 0 | Against |
| Invesco | 0 | 203,548 | 0 | 0 | Against |
| Victory Capital | 180,836 | 0 | 0 | 0 | For |
| TIAA | 121,036 | 0 | 0 | 0 | For |
| Equitable | 97,860 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 90,854 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 76,601 | 0 | 0 | 0 | For |
| Russell Investments | 60,914 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 53,817 | 0 | 0 | 0 | For |
| Hartford | 51,244 | 0 | 0 | 0 | For |
| Lincoln Financial | 48,298 | 0 | 0 | 0 | For |
| JPMorgan | 48,262 | 0 | 0 | 0 | For |
| Tema ETF Trust | 46,453 | 0 | 0 | 0 | For |
| Northern Trust | 41,496 | 0 | 0 | 0 | For |
| John Hancock | 36,453 | 0 | 0 | 0 | For |
Fund voting reports, all 71 managers: 16,008,184 for, 457,264 against, 2,459 abstained. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 10,287,746 | 0 | 0 | 0 | For |
| Fidelity | 8,858,763 | 0 | 0 | 0 | For |
| Janus Henderson | 2,962,192 | 4,657 | 0 | 0 | For |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | 2,899,400 | 0 | 0 | 0 | For |
| Paradigm Biocapital Advisors LP | 2,554,335 | 0 | 0 | 0 | For |
| Woodline Partners LP | 1,530,833 | 0 | 0 | 0 | For |
| EcoR1 Capital, LLC | 1,469,818 | 0 | 0 | 0 | For |
| Logos Global Management LP | 1,450,000 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,439,175 | 0 | 0 | 0 | For |
| BlackRock | 1,110,224 | 0 | 0 | 0 | For |
| Cormorant Asset Management, LP | 898,076 | 0 | 0 | 0 | For |
| State Street | 846,846 | 12,494 | 0 | 0 | For |
| FRANKLIN ADVISERS INC | 813,175 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 790,461 | 0 | 0 | 0 | For |
| Point72 | 779,466 | 0 | 0 | 0 | For |
| ORBIMED ADVISORS LLC | 720,000 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 592,586 | 0 | 0 | 0 | For |
| MPM BioImpact LLC | 419,235 | 0 | 0 | 0 | For |
| Putnam | 365,744 | 0 | 0 | 0 | For |
| Alyeska Investment Group, L.P. | 343,091 | 0 | 0 | 0 | For |
| Citadel | 338,675 | 0 | 0 | 0 | For |
| Victory Capital | 286,002 | 0 | 0 | 0 | For |
| Wellington | 278,265 | 0 | 0 | 0 | For |
| Charles Schwab | 276,724 | 0 | 0 | 0 | For |
| Ensign Peak Advisors, Inc | 268,095 | 0 | 0 | 0 | For |
Institutional-manager reports, all 181 managers: 45,065,206 for, 856,880 against, 4,905 not voted, 11,262 1 year. Showing the 25 largest; every one is in the interactive database (link above).
Combines 4 wordings of this item as funds reported it.
99.9% Fund and manager reports combined; may count the same shares twice · no official result
Description as filed by funds: Indication, on an advisory basis, of the preferred frequency of holding future Say-On-Pay votes on the compensation of our named executive officers.
Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice). The figure above is FOR ÷ (FOR + AGAINST + WITHHELD) of the shares these managers voted; abstained and unvoted shares are in neither half, and these managers are a subset of all shareholders, not the meeting result.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Vanguard | 0 | 0 | 0 | 0 | -- |
| JANUS INVESTMENT FUND | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| FRANKLIN STRATEGIC SERIES | 0 | 0 | 0 | 0 | -- |
| Putnam | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| Columbia Threadneedle | 0 | 0 | 0 | 0 | -- |
| Aberdeen | 0 | 0 | 0 | 0 | -- |
| Invesco | 0 | 0 | 0 | 0 | -- |
| Victory Capital | 0 | 0 | 0 | 0 | -- |
| TIAA | 0 | 0 | 0 | 0 | -- |
| Equitable | 0 | 0 | 0 | 0 | -- |
| Bridge Builder Trust | 0 | 0 | 0 | 0 | -- |
| Delaware/Macquarie | 0 | 0 | 0 | 0 | -- |
| Russell Investments | 0 | 0 | 0 | 0 | -- |
| QUANTITATIVE MASTER SERIES LLC | 0 | 0 | 0 | 0 | -- |
| Hartford | 0 | 0 | 0 | 0 | -- |
| Lincoln Financial | 16,621 | 0 | 0 | 0 | For |
| JPMorgan | 0 | 0 | 0 | 0 | -- |
| Tema ETF Trust | 0 | 0 | 0 | 0 | -- |
| Northern Trust | 0 | 0 | 0 | 0 | -- |
| John Hancock | 0 | 0 | 0 | 0 | -- |
Fund voting reports, all 71 managers: 16,621 for, 2,459 abstained, 16,448,827 1 year. Showing the 25 largest; every one is in the interactive database (link above).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 0 | 0 | 0 | 0 | -- |
| Fidelity | 0 | 0 | 0 | 0 | -- |
| Janus Henderson | 0 | 0 | 0 | 0 | -- |
| Paradigm Biocapital Advisors LP | 0 | 0 | 0 | 0 | -- |
| Woodline Partners LP | 0 | 0 | 0 | 0 | -- |
| EcoR1 Capital, LLC | 0 | 0 | 0 | 0 | -- |
| Logos Global Management LP | 0 | 0 | 0 | 0 | -- |
| T. Rowe Price | 0 | 0 | 0 | 0 | -- |
| BlackRock | 0 | 0 | 0 | 0 | -- |
| Cormorant Asset Management, LP | 0 | 0 | 0 | 0 | -- |
| State Street | 0 | 0 | 0 | 0 | -- |
| FRANKLIN ADVISERS INC | 0 | 0 | 0 | 0 | -- |
| GEODE CAPITAL MANAGEMENT, LLC | 0 | 0 | 0 | 0 | -- |
| Point72 | 0 | 0 | 0 | 0 | -- |
| ORBIMED ADVISORS LLC | 0 | 0 | 0 | 0 | -- |
| PICTET ASSET MANAGEMENT SA | 0 | 0 | 0 | 0 | -- |
| MPM BioImpact LLC | 0 | 0 | 0 | 0 | -- |
| Putnam | 0 | 0 | 0 | 0 | -- |
| Alyeska Investment Group, L.P. | 0 | 0 | 0 | 0 | -- |
| Citadel | 0 | 0 | 0 | 0 | -- |
| Victory Capital | 0 | 0 | 0 | 0 | -- |
| Wellington | 0 | 0 | 0 | 0 | -- |
| Charles Schwab | 0 | 0 | 0 | 0 | Not Voted |
| Ensign Peak Advisors, Inc | 0 | 0 | 0 | 0 | -- |
| Invesco | 0 | 0 | 0 | 0 | -- |
Institutional-manager reports, all 174 managers: 366,585 for, 172 against, 38,100 abstained, 4,905 not voted, 42,217,226 1 year, 268,826 3 year. Showing the 25 largest; every one is in the interactive database (link above).
99.9% Approved · of votes cast
Prior year: 100.0% for (June 26, 2024 meeting) unchanged
Description as filed by funds: TO RATIFY THE SELECTION BY THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF ERNST & YOUNG LLP AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR OUR FISCAL YEAR ENDING DECEMBER 31, 2025.
JANUX THERAPEUTICS INC.’s own tally for this item (“2. Ratification of the Selection of Independent Registered Public Accounting Firm”): 56,152,990 for, 27,381 against — passed, per its Form 8-K filed June 13, 2025 (Item 5.07).
Reported outcome: Approved, in the filing’s own words: “Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The Company's stockholders ratified the selection by the Audit Committee of the Company's Board of Directors of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal …”
Support: 99.9% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.
The 71 asset managers below reported 16,465,169 for, 279 against, 2,459 abstained.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Fidelity | 7,262,889 | 0 | 0 | 0 | For |
| Vanguard | 2,207,727 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 1,328,416 | 0 | 0 | 0 | For |
| BlackRock | 1,319,820 | 0 | 0 | 0 | For |
| T. Rowe Price | 1,066,406 | 0 | 0 | 0 | For |
| FRANKLIN STRATEGIC SERIES | 445,252 | 0 | 0 | 0 | For |
| Putnam | 333,552 | 0 | 0 | 0 | For |
| Charles Schwab | 276,724 | 0 | 0 | 0 | For |
| State Street | 258,799 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 238,425 | 0 | 0 | 0 | For |
| Aberdeen | 224,788 | 0 | 0 | 0 | For |
| Invesco | 203,548 | 0 | 0 | 0 | For |
| Victory Capital | 180,836 | 0 | 0 | 0 | For |
| TIAA | 121,036 | 0 | 0 | 0 | For |
| Equitable | 97,860 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 90,854 | 0 | 0 | 0 | For |
| Delaware/Macquarie | 76,601 | 0 | 0 | 0 | For |
| Russell Investments | 60,914 | 0 | 0 | 0 | For |
| QUANTITATIVE MASTER SERIES LLC | 53,817 | 0 | 0 | 0 | For |
| Hartford | 51,244 | 0 | 0 | 0 | For |
| Lincoln Financial | 48,298 | 0 | 0 | 0 | For |
| JPMorgan | 48,262 | 0 | 0 | 0 | For |
| Tema ETF Trust | 46,453 | 0 | 0 | 0 | For |
| Northern Trust | 41,496 | 0 | 0 | 0 | For |
| John Hancock | 36,453 | 0 | 0 | 0 | For |
Showing the 25 largest of 71 asset managers. All 71 are in the interactive database (link above).
Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 59,168,490 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Fidelity | 12.27% |
| 2 | Vanguard | 3.73% |
| 3 | JANUS INVESTMENT FUND | 2.25% |
| 4 | BlackRock | 2.23% |
| 5 | T. Rowe Price | 1.80% |
| 6 | FRANKLIN STRATEGIC SERIES | 0.75% |
| 7 | Putnam | 0.56% |
| 8 | Charles Schwab | 0.47% |
| 9 | State Street | 0.44% |
| 10 | Columbia Threadneedle | 0.40% |
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | RA CAPITAL MANAGEMENT, L.P. | 17.39% |
| 2 | Fidelity | 14.97% |
| 3 | Janus Henderson | 5.01% |
| 4 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.90% |
| 5 | Paradigm Biocapital Advisors LP | 4.32% |
| 6 | Woodline Partners LP | 2.59% |
| 7 | EcoR1 Capital, LLC | 2.48% |
| 8 | Logos Global Management LP | 2.45% |
| 9 | T. Rowe Price | 2.43% |
| 10 | BlackRock | 1.88% |
As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.
| Holder | Shares | % outstanding | Source, as of |
|---|---|---|---|
| Entities affiliated with RA Capital Healthcare Fund, L.P. | 12,175,165 | — | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
| RA Capital Management, L.P. | 11,971,377 | — | Schedule 13D, filed March 10, 2025 |
| FMR (Fidelity) | 8,884,072 | — | Form 13F, quarter ended March 31, 2025 |
| FMR LLC | 7,824,674 | — | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
| JANUS HENDERSON GROUP PLC | 4,196,409 | — | Schedule 13G, filed May 15, 2026 |
| Entities affiliated with Janus Henderson Group plc | 3,562,402 | — | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
| Entities affiliated with Paradigm BioCapital Advisors GP LLC | 3,515,986 | — | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
| Prosight Management, LP | 3,150,970 | — | Schedule 13G, filed February 6, 2026 |
| Entities affiliated with Adage Capital Management, L.P. | 3,061,750 | — | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
| Bregua Corporation | 2,999,990 | — | Proxy statement (DEF 14A), proxy filed April 25, 2025 |
Percentages above are of 59,168,490 shares outstanding, as reported by JANUX THERAPEUTICS INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.
At JANUX THERAPEUTICS INC.'s shareholder meeting held June 11, 2025, in the 2024-2025 proxy season, 232 asset managers reported votes on at least one item in their SEC Form N-PX filings, covering 1,844 separate fund positions. Their filings are grouped here into 6 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Approval, on an advisory basis, of the compensation of our named executive officers… — JANUX THERAPEUTICS INC.'s filing reports the proposal as approved, with 98% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: JANUX THERAPEUTICS INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 13, 2025.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from JANUX THERAPEUTICS INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.
JANUX THERAPEUTICS INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.
Proxy Votes Now, “JANUX THERAPEUTICS (JANX) 2025 Annual Meeting: Vote Results”, https://proxyvotesnow.com/company/janux-therapeutics-inc/2025 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.